AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced the appointment of Märta Segerdahl, MD, PhD, Associate professor, as Chief Medical Officer (CMO). She will be a member of AlzeCure’s executive management team and succeeds An van Es-Johansson, MD, currently CMO and Head of Development, and previously member of the Board, who will continue working for AlzeCure as an advisor.

Dr. Segerdahl will take on the position as CMO on April 1 and will have the overall medical responsibility for AlzeCures’s drug development candidates and will lead the clinical development organization. Dr. Segerdahl has more than 15 years of industry experience from both big pharma and small biotech, with various senior positions in pharmaceutical drug development, focusing on neuroscience. Recent positions include CMO at Asarina Pharma ApS, Chief Medical Specialist at Lundbeck A/S, Senior Medical Director Medical Intelligence at Grünenthal GmbH, and Global Medical Science Director Emerging Cognition at AstraZeneca.

“We are delighted to have Märta joining our team. Her expertise in CNS and solid experience in leading clinical development and building development organizations will strengthen our clinical capacity as we are now maturing the clinical portfolio. Her experience from both big pharma and biotech will also be instrumental in our business development efforts and partnering discussions,” said Martin Jönsson, CEO of AlzeCure Pharma.

“I am thrilled to join the AlzeCure team at this important time in the company’s development. I hope to be able to apply my many years of clinical experience within neurology and pain as well as my clinical drug development skills to progress AlzeCure’s drug candidates to the next level”, said Dr. Segerdahl.

”I would also like to express my sincere thanks to Dr van Es-Johansson who has had a decisive role in driving our Development organization and our clinical portfolio through important studies and phases. We look forward working with her as an advisor as we move our exciting project portfolio forward”, said Martin Jönsson.